Nonalcoholic steatohepatitis (NASH)

It is estimated that by 2030, NASH will be the #1 most frequent reason for liver transplants in the US

Assessment of liver fibrosis has traditionally relied on costly and invasive liver biopsy that requires a specialist, may not be representative of the amount of fibrosis, and carries a risk of life-threatening complications.

    ELF Infographic

    The ELFTM Test is a routine blood test proven to predict progression to cirrhosis and liver related events in patient with advanced fibrosis due to NASH1

    • The only blood test with a prognostic claim in advanced fibrosis due to NASH
    • Simplifies and accelerates the identification of patients with advanced fibrosis due to NASH, at risk of disease progression
    • Facilitates more frequent prognostic assessments
    • Available to all patients

    The ELF Test enables accessible, effortless prognostic risk assessment in advanced fibrosis due to NASH, improving patient care by stratifying those most at risk of progressing to cirrhosis and liver related events1

    1